InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Generics would be shut out of PTAB under Hatch amendment

Michael Loney, New York


The Hatch-Waxman Integrity Act of 2018 would require a generic manufacturer wishing to challenge a brand-name drug patent to choose between Hatch-Waxman litigation and IPR, which one observer describes as a “Hobson’s choice”

US Senator Orrin Hatch has filed an amendment, the Hatch-Waxman Integrity Act of 2018, that would force a choice between the abbreviated processes under the Hatch-Waxman Act and challenging the brand patents at the Patent Trial and Appeal Board.

Hatch’s...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

Most read articles

Latest Country Updates

Supplements